Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

 Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

Shots:

  • The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib, 600mg, bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with an epithelial ovarian, fallopian tube or primary peritoneal cancer
  • The P-III ARIEL3 study results: IIT population & BRCA mutation, Mean QA-PFS in (12.02 vs 5.74 & 15.28 vs 5.92 mos.); Mean Q-TWiST (13.32 vs 6.44 & 16.42 vs 6.70 mos.); Q-TWiST (13.16 vs 6.40 & 16.24 vs 6.68 mos.) respectively
  • Rubraca (rucaparib) is an oral PARP1, PARP2 and PARP3 inhibitor and has received FDA’s approval as a monothx. for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in Apr’18

Click here to read full press release/ article | Ref: BusinessWire | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post